Brief: Curvebeam Ai Says FDA 510(K) Clearance For Bmd Module For Mdct Targeted For H2
30/04/2026 02:36
April 30 (Reuters) - Curvebeam AI Ltd CVB.AX: FDA 510(K) CLEARANCE FOR BMD MODULE FOR MDCT TARGETED FOR H2 CY26 Further company coverage: CVB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Curvebeam AI
See all newsAustralia's CurveBeam rises on Chinese approval of medical imaging device
Brief: Curvebeam AI Seeks Trading Halt
Australia's CurveBeam AI shares double in value on FDA nod for CT scan tech
Australia's CurveBeam AI on track for best day in 3 weeks on premium placement
Brief: Curvebeam AI Secures A$5 Million Placement, A$1 Million Share Purchase Plan